Cargando…
From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema
Empyema, a severe complication of pneumonia, trauma, and surgery is characterized by fibrinopurulent effusions and loculations that can result in lung restriction and resistance to drainage. For decades, efforts have been focused on finding a universal treatment that could be applied to all patients...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811368/ https://www.ncbi.nlm.nih.gov/pubmed/35126140 http://dx.doi.org/10.3389/fphar.2021.806393 |
_version_ | 1784644419848241152 |
---|---|
author | Karandashova, Sophia Florova, Galina Idell, Steven Komissarov, Andrey A. |
author_facet | Karandashova, Sophia Florova, Galina Idell, Steven Komissarov, Andrey A. |
author_sort | Karandashova, Sophia |
collection | PubMed |
description | Empyema, a severe complication of pneumonia, trauma, and surgery is characterized by fibrinopurulent effusions and loculations that can result in lung restriction and resistance to drainage. For decades, efforts have been focused on finding a universal treatment that could be applied to all patients with practice recommendations varying between intrapleural fibrinolytic therapy (IPFT) and surgical drainage. However, despite medical advances, the incidence of empyema has increased, suggesting a gap in our understanding of the pathophysiology of this disease and insufficient crosstalk between clinical practice and preclinical research, which slows the development of innovative, personalized therapies. The recent trend towards less invasive treatments in advanced stage empyema opens new opportunities for pharmacological interventions. Its remarkable efficacy in pediatric empyema makes IPFT the first line treatment. Unfortunately, treatment approaches used in pediatrics cannot be extrapolated to empyema in adults, where there is a high level of failure in IPFT when treating advanced stage disease. The risk of bleeding complications and lack of effective low dose IPFT for patients with contraindications to surgery (up to 30%) promote a debate regarding the choice of fibrinolysin, its dosage and schedule. These challenges, which together with a lack of point of care diagnostics to personalize treatment of empyema, contribute to high (up to 20%) mortality in empyema in adults and should be addressed preclinically using validated animal models. Modern preclinical studies are delivering innovative solutions for evaluation and treatment of empyema in clinical practice: low dose, targeted treatments, novel biomarkers to predict IPFT success or failure, novel delivery methods such as encapsulating fibrinolysin in echogenic liposomal carriers to increase the half-life of plasminogen activator. Translational research focused on understanding the pathophysiological mechanisms that control 1) the transition from acute to advanced-stage, chronic empyema, and 2) differences in outcomes of IPFT between pediatric and adult patients, will identify new molecular targets in empyema. We believe that seamless bidirectional communication between those working at the bedside and the bench would result in novel personalized approaches to improve pharmacological treatment outcomes, thus widening the window for use of IPFT in adult patients with advanced stage empyema. |
format | Online Article Text |
id | pubmed-8811368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88113682022-02-04 From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema Karandashova, Sophia Florova, Galina Idell, Steven Komissarov, Andrey A. Front Pharmacol Pharmacology Empyema, a severe complication of pneumonia, trauma, and surgery is characterized by fibrinopurulent effusions and loculations that can result in lung restriction and resistance to drainage. For decades, efforts have been focused on finding a universal treatment that could be applied to all patients with practice recommendations varying between intrapleural fibrinolytic therapy (IPFT) and surgical drainage. However, despite medical advances, the incidence of empyema has increased, suggesting a gap in our understanding of the pathophysiology of this disease and insufficient crosstalk between clinical practice and preclinical research, which slows the development of innovative, personalized therapies. The recent trend towards less invasive treatments in advanced stage empyema opens new opportunities for pharmacological interventions. Its remarkable efficacy in pediatric empyema makes IPFT the first line treatment. Unfortunately, treatment approaches used in pediatrics cannot be extrapolated to empyema in adults, where there is a high level of failure in IPFT when treating advanced stage disease. The risk of bleeding complications and lack of effective low dose IPFT for patients with contraindications to surgery (up to 30%) promote a debate regarding the choice of fibrinolysin, its dosage and schedule. These challenges, which together with a lack of point of care diagnostics to personalize treatment of empyema, contribute to high (up to 20%) mortality in empyema in adults and should be addressed preclinically using validated animal models. Modern preclinical studies are delivering innovative solutions for evaluation and treatment of empyema in clinical practice: low dose, targeted treatments, novel biomarkers to predict IPFT success or failure, novel delivery methods such as encapsulating fibrinolysin in echogenic liposomal carriers to increase the half-life of plasminogen activator. Translational research focused on understanding the pathophysiological mechanisms that control 1) the transition from acute to advanced-stage, chronic empyema, and 2) differences in outcomes of IPFT between pediatric and adult patients, will identify new molecular targets in empyema. We believe that seamless bidirectional communication between those working at the bedside and the bench would result in novel personalized approaches to improve pharmacological treatment outcomes, thus widening the window for use of IPFT in adult patients with advanced stage empyema. Frontiers Media S.A. 2022-01-20 /pmc/articles/PMC8811368/ /pubmed/35126140 http://dx.doi.org/10.3389/fphar.2021.806393 Text en Copyright © 2022 Karandashova, Florova, Idell and Komissarov. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Karandashova, Sophia Florova, Galina Idell, Steven Komissarov, Andrey A. From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema |
title | From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema |
title_full | From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema |
title_fullStr | From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema |
title_full_unstemmed | From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema |
title_short | From Bedside to the Bench—A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema |
title_sort | from bedside to the bench—a call for novel approaches to prognostic evaluation and treatment of empyema |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811368/ https://www.ncbi.nlm.nih.gov/pubmed/35126140 http://dx.doi.org/10.3389/fphar.2021.806393 |
work_keys_str_mv | AT karandashovasophia frombedsidetothebenchacallfornovelapproachestoprognosticevaluationandtreatmentofempyema AT florovagalina frombedsidetothebenchacallfornovelapproachestoprognosticevaluationandtreatmentofempyema AT idellsteven frombedsidetothebenchacallfornovelapproachestoprognosticevaluationandtreatmentofempyema AT komissarovandreya frombedsidetothebenchacallfornovelapproachestoprognosticevaluationandtreatmentofempyema |